Effect of vitamin D supplementation on nonalcoholic fatty liver disease in type 2 diabetic patients
Not Applicable
- Conditions
- nonalcoholic fatty liver.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT2014020816528N1
- Lead Sponsor
- Shahrekord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 115
Inclusion Criteria
known case of type II diabetes who have been treated for at least 6 months
exclusion criteria:
positive history of alcohol use; positive history of hepatitis B or C; chronic liver or renal disease; consumption of drugs known to cause fatty liver change (such as estrogen, metotrexate, Tamoxifen, Tetracyclin, Oral contraceptive pills, sodium valporate); pregnancy or lactation; positive history of thyroid disease
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver enzymes(AST, ALT, GGT). Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method ipid profile ( cholesterol, HDL, LDL, TG). Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: spectrophotometry.;HbA1C. Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: HPLC.;(fasting blood sugar) FBS. Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: spectrophotometry.